PROCEPT BioRobotics (NASDAQ:PRCT) Stock Price Down 4.8% – Should You Sell?

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) dropped 4.8% on Wednesday . The company traded as low as $21.82 and last traded at $21.7910. 45,548 shares traded hands during trading, a decline of 97% from the average session volume of 1,611,013 shares. The stock had previously closed at $22.89.

More PROCEPT BioRobotics News

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Negative Sentiment: The lawsuit alleges that PROCEPT made material misstatements or omissions about demand for its surgical-system handpieces, the gap between handpiece sales and procedure volumes, and customer inventory levels. The allegations are unproven, but they raise concerns about the sustainability and quality of the company’s revenue growth. Hagens Berman class-action notice
• Negative Sentiment: According to the legal complaints and investor alerts, repeated late-quarter bulk discounts allegedly contributed to excess inventory at customers and masked weaker unit handpiece performance. The disclosures reportedly followed an approximately 18% share-price decline, adding to investor concerns about execution and future growth. PROCEPT inventory issues class-action announcement
• Negative Sentiment: The volume of notices from firms including Kirby McInerney, Hagens Berman, Kahn Swick & Foti, Rosen, Kaplan Fox and others increases the visibility of PROCEPT’s litigation risk. Potential costs include legal expenses, reputational damage and a possible settlement or damages claim, although the ultimate outcome remains uncertain. Kirby McInerney shareholder alert

Wall Street Analyst Weigh In

PRCT has been the subject of several recent research reports. Wall Street Zen upgraded PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Evercore set a $23.00 price objective on shares of PROCEPT BioRobotics in a research note on Wednesday, August 5th. UBS Group lowered shares of PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 target price for the company. in a report on Tuesday, July 28th. Robert W. Baird set a $20.00 price target on shares of PROCEPT BioRobotics in a report on Wednesday, August 5th. Finally, TD Cowen dropped their price target on shares of PROCEPT BioRobotics from $34.00 to $28.00 and set a “buy” rating on the stock in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, PROCEPT BioRobotics currently has a consensus rating of “Hold” and a consensus target price of $28.00.

PROCEPT BioRobotics Price Performance

The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.35 and a current ratio of 6.55. The stock’s 50 day simple moving average is $21.19 and its two-hundred day simple moving average is $24.51. The firm has a market capitalization of $1.26 billion, a PE ratio of -11.31 and a beta of 0.89.

PROCEPT BioRobotics (NASDAQ:PRCT) last issued its earnings results on Tuesday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.01). The company had revenue of $94.50 million during the quarter, compared to analysts’ expectations of $92.77 million. PROCEPT BioRobotics had a negative net margin of 32.53% and a negative return on equity of 30.62%. The firm’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.35) earnings per share. On average, sell-side analysts forecast that PROCEPT BioRobotics Corporation will post -1.67 EPS for the current year.

Insider Transactions at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry L. Wood bought 23,900 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were purchased at an average cost of $20.85 per share, with a total value of $498,315.00. Following the purchase, the chief executive officer directly owned 23,900 shares in the company, valued at approximately $498,315. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have sold 1,000 shares of company stock worth $28,480 in the last 90 days. 4.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On PROCEPT BioRobotics

Institutional investors and hedge funds have recently modified their holdings of the company. Algert Global LLC boosted its holdings in shares of PROCEPT BioRobotics by 63.8% in the 2nd quarter. Algert Global LLC now owns 41,498 shares of the company’s stock valued at $937,000 after buying an additional 16,160 shares in the last quarter. Biondo Investment Advisors LLC purchased a new stake in PROCEPT BioRobotics in the second quarter valued at $1,335,000. William Blair Investment Management LLC purchased a new stake in PROCEPT BioRobotics in the second quarter valued at $16,020,000. Ieq Capital LLC acquired a new position in PROCEPT BioRobotics in the second quarter valued at $934,000. Finally, BlackRock Inc. acquired a new position in PROCEPT BioRobotics in the second quarter valued at $109,961,000. Institutional investors and hedge funds own 89.46% of the company’s stock.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.